Skip to main content
Equibles
LFST logo

LFST · LifeStance Health Group, Inc. · Metrics

Track LFST — free

Use LFST with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LFST.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$12.41 +0.08 (+0.65%)
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$4.71B
Shares
382.06M
Volume · Oct 22 2.04M Avg daily vol (3M) 4.25M

LFST metrics

96 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$12.33
Market cap
$4.71B

Price action

20 metrics
Price change (1W)
-1.5%
Price change (30D)
-1.8%
Price change (3M)
+12.0%
Price change (6M)
+78.4%
Price change (YTD)
+75.1%
Price change (1Y)
+137.1%
Trailing year
Price change (5Y)
+5.5%
52-week high
$13.38
52-week low
$4.81
Change from 52-week high
-7.8%
Change from 52-week low
+156.3%
Annualized volatility
52.6%
Annualized volatility (3M)
38.9%
Beta
0.6
RSI (14D)
52.5
Price vs SMA 50
-0.4%
Price vs SMA 200
+35.0%
Avg volume (3M)
4.25M
Relative volume
0.8
Average dollar volume
$51.48M

Company

3 metrics
Sector
Healthcare
Industry
Medical Care Facilities
Shares outstanding
382.06M

Valuation

12 metrics
P / E (TTM)
92.3
Trailing earnings · reciprocal yield 1.1%
PEG ratio
—
EV / revenue
3.0×
reciprocal yield 33.6%
EV / EBITDA
39.0×
reciprocal yield 2.6%
EV / EBIT
60.1×
reciprocal yield 1.7%
P / sales
2.9×
reciprocal yield 33.9%
P / book
3.2
reciprocal yield 31.6%
FCF yield
3.7%
TTM · current market cap
Buyback yield
—
P / FCF
26.8
reciprocal yield 3.7%
P / operating cash flow
21.4
reciprocal yield 4.7%
Earnings yield
1.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
2.4×
reciprocal yield 42.2%
EV / revenue historical average (5Y)
2.6×
reciprocal yield 38.6%
EV / EBIT historical average (3Y)
151.1×
reciprocal yield 0.7%
EV / EBIT historical average (5Y)
151.1×
reciprocal yield 0.7%
EV / EBITDA historical average (3Y)
90.8×
reciprocal yield 1.1%
EV / EBITDA historical average (5Y)
90.8×
reciprocal yield 1.1%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-05
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
4.9%
Trailing 12 months
Net margin
3.2%
Gross profit (TTM)
—
Operating profit (TTM)
$78.43M
Net income (TTM)
$50.60M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
11.0%
Effective tax rate
24.5%

Per share

11 metrics
Revenue per diluted share (TTM)
$4.04
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$0.20
EBITDA per diluted share (TTM)
$0.31
Net income per diluted share (TTM)
$0.13
Operating cash flow per diluted share (TTM)
$0.56
Free cash flow per diluted share (TTM)
$0.44
Capital expenditures per diluted share (TTM)
$0.11
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$0.18
Book value per share
$3.92

Growth

11 metrics
Revenue growth YoY
+26.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.58B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.1%
Year over year · more shares
Revenue CAGR (3Y)
+18.3%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
3.4%
Return on assets
2.3%
Debt / equity
0.2
Current ratio
1.4
EBITDA (TTM)
$120.80M
Free cash flow (TTM)
$173.91M
Quick ratio
1.4
Interest coverage
7.8
Net debt / EBITDA
0.4
Return on invested capital
3.9%
Trailing 12 months
Net cash
−$47.55M
Latest balance sheet
Cash & equivalents
$225.94M
Total assets
$2.18B
Total debt
$273.49M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$217.87M
Capital expenditures (TTM)
$43.96M
R&D (TTM)
—
SG&A (TTM)
$398.86M
Stock compensation (TTM)
$69.95M
R&D / revenue
—
Stock compensation / revenue
4.4%

Ownership (13F)

9 metrics
13F filers
293
13F filer change QoQ
+64
Institutional ownership
98.5%
Conviction holders (share of 13F filers)
0.7%
Crowding (high-turnover and private-fund holders)
23.0%
Private-fund adviser ownership
22.7%
Active holders' share change QoQ
-5.2%
Holder tenure
15.2
Price vs estimated holder cost
+51.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
15.5%

Short interest

3 metrics
Short interest
4.1%
Latest settlement · 2.6 days to cover
Days to cover
2.6d
Short-squeeze score
53 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$7.64M
Insider-sentiment score
13 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1845257 CUSIP 53228F101 13F (30d) 37 filings 37 filers Visit website Investor relations